A randomized phase III trial is currently assessing the efficacy and safety of disitamab vedotin versus TPC in patients with low HER2-expressing metastatic breast cancer who experienced disease progress during or after one line of therapy for metastatic disease (NCT04400695) [1,6,68]. This evidence concerns the gene ERBB2 and metastatic neoplasm.